



ELSEVIER

# Comment bénéficiaire de l'accord Couperin et publier en libre accès avec Elsevier?

Parcours Auteur



# 1. Notions clés:

Terminologie	Définition
Submitting Corresponding Author / Auteur Correspondant	<p>“Submitting corresponding author” est l’auteur qui soumet l’article à Elsevier et qui reste en contact avec l’éditeur du début à la fin.</p> <p>C'est l'auteur qui fait le choix de la publication au nom du groupe d'auteurs.</p> <p>Chaque article a un auteur correspondant.</p>
Acceptance Date	<p>Il s'agit de la date à laquelle la revue accepte l'article pour publication.</p>
Elsevier OA Platform	<p>Elsevier OA Platform (EOAP) est une interface simple qui présente aux administrateurs institutionnels les articles en libre accès éligibles à l'accord.</p> <p>Les administrateurs de l'institution valident l'éligibilité de l'auteur à un accord OA.</p>
Gold Open Access	<p>La version finale de l'article publié est mise gratuitement et immédiatement à la disposition de toutes et tous. Un auteur peut publier en « Gold Open Access » dans une revue Open Access OU dans une revue Hybride qui offre un Open Access.</p>

## 2. Critères d'éligibilité:

Critère	Description
Acceptance date	La date d'acceptation de l'article doit se situer dans la période de souscription de votre institution.
Author affiliation	L'auteur correspondant doit être affilié à une institution participant à l'accord.
Journal title	L'article doit être soumis et accepté dans une revue participante.
APC available	Il reste des APC pour l'année en cours.

### 3. Aperçu de l'accord:

Journal Bucket	Agreement
Core Hybride/ Core Gold	Les auteurs correspondants éligibles ont le coût de publication en libre accès (APC) couvert par l'accord après validation dans EOAP. Quota centralisé de 11138/11268/11410/11566 pour 2024-2027
Cell Press/Lancet Hybride et Gold	Les auteurs correspondants éligibles bénéficient d'une réduction de 10 % lors de la validation dans EOAP.

# Options de publication lors de la soumission (Editorial Manager)

5

Dans le cadre du processus de soumission, une fois que l'auteur a téléchargé les fichiers du manuscrit, l'auteur correspondant fournit les détails de son affiliation.

**Authors**

Please enter options and

**Hint:** start return the n department

You may rec Current Aut

**Current Aut**

.../

**+ Add Ano**

**Edit Author Details**

**Mr. Bharath Aradhyula [Corresponding Author] [First Author] [You]**

[Insert Special Characters](#)

**Your Given/First Name\***

Middle Name

**Your Family/Last Name\***

Academic Degree(s)

**Your E-mail Address\***

ORCID  [Fetch/Register](#)

[What is ORCID?](#)

**Institution\***

Start typing to display potentially matching institutions. [i](#)

Country or Region

Save these changes to my user registration as well

This is the corresponding author [i](#)

**Next**

**+ Funding Info**

**Back** **Save & Submit Later** **Build PDF for Approval**

L'auteur correspondant fournit également les coordonnées du financeur, le cas échéant. En cliquant sur « Build PDF for Approval », l'auteur passe à la page suivante.

+ Add Another Author

↓ Next

### Funding Information

Please choose a funding source from the list that displays as you start to enter the funder's name. If you are unable to make a selection from the list you can continue to enter the entire funder's name. Then enter the award number and select the award recipient.

If providing details for two or more organizations, please list the organization(s) that provided the most funding first, as this will help us determine the publishing options for your article.

**Required** ✓

#### Current Funding Sources List

There are currently no Funding Sources

+ Add a Funding Source

Funding information is required

#### Add New Funding Source

Insert Special Characters

Find a Funder: Milliman


Award Number: GT123

Grant Recipient: Arnold Stanly

← Back   Save & Submit Later   Build PDF for Approval →

Vous ne devrez fournir qu'une seule fois les détails relatifs à l'affiliation et au financeur, car nous les copierons après l'acceptation.

**Le système présente des informations sur les options de publication et l'auteur indique son choix de lors de la soumission seulement à titre indicatif.**

 International Journal of Pharmaceutics

[Home](#) [Main Menu](#) [Submit a Manuscript](#) [About](#) [Help](#)

## Elsevier Publishing Options

### Please indicate your Publishing Options

This is a hybrid journal. The journal publishes both subscription and OA articles. We will present your personalized Publishing Options based on the Institution and Funding details you have given us. Please note that at this stage in your submission, you are only indicating your preference. We will ask you to make a final choice after the journal has accepted your manuscript.


[Publishing Options](#)


[Cancel](#)

[Proceed](#)



# Options de publication dans une revue Hybride

**i** Based on the information you have provided, these are your publishing options.  
If the journal accepts your article, you can change your mind about these options.  
Note: editors and reviewers can only see your selection after acceptance.  
This is a Transformative Journal 

iqwhnoief 





## Gold Open Access

Publish as an Open Access article

Make my final published article available to everyone upon acceptance.

I am an author affiliated with the **Nantes University**. As there is an [agreement in place between the French higher education and research institutions consortium \(Couperin\) and Elsevier](#) to cover the APC (Article Publishing Charge) for publishing Open Access, I do not have to pay an APC if **all** of the following criteria are met:

- My institution has APCs available by the time the journal accepts the article
- My institution approves using the agreement funds to pay the APC

To pay on acceptance	
 Only applicable if article accepted	
 APC	Price EUR 3,120.00
 Institutional Agreement Discount	- 3,120.00
	To pay (on validation) <b>0.00</b>

## Subscription

Publish as a subscription article

I will publish my article subscription, making my final published article immediately available to journal subscribers, and to other groups as part of [Elsevier's programs](#).

I understand I can immediately share my article within my institution and privately with collaborators, and share my accepted manuscript publicly in my institution's repository after 12 months. I have additional article sharing rights outlined [here](#).

## Options de publication dans Cell Press/Lancet

- Indication à l'auteur qu'il devra fournir un bon de commande (en cours d'implémentation)



**i** These are the available publishing options.  
If the journal accepts your article, you can change your mind about these options.  
Note: editors and reviewers can only see your selection after acceptance.

IGlug

### Gold Open Access

Publish as an Open Access article

Make my published article available to everyone upon acceptance.


As a corresponding author affiliated with the University of Avignon, upon validation, **the agreement between the French institutions and Elsevier will cover the APC with a valid purchase order number after acceptance.**

I will need to enter the valid PO number as part of the post acceptance journey. For guidance on how to collect PO number from my institution, I can refer to this [link](#).


#### To pay on acceptance

**i** Only applicable if article accepted

Price  
EUR 4,880.00

 Institutional Agreement Discount  
- 488.00

**To pay** (on validation)

 (Excluding taxes)  
EUR 4,392.00



# Options de publication après acceptation

**L'Auteur  
Correspondant reçoit  
un courriel après  
l'acceptation, avec un  
lien unique pour  
compléter le  
processus et choisir  
les options de  
publication.**

**Puis, cliquez sur le  
"Complete the Rights  
and Access form".**

<b>Test article</b>		
Corresponding author	Mr. Bharath Aradhya	
E-mail address	v.aradhya@elsevier.com	
Journal	Infection, Disease & Health - TEST	
Our reference	IDH119	
PII	S4444-2092(22)00016-5	


**Welcome Mr. Aradhya,**  
To help us finalize the publication of your article please complete the publishing form(s) below.  
**Note:** you will receive a confirmation e-mail after completing each form.

 Information you may need to provide to complete the forms 

### Rights and Access


[Complete the rights and access form >](#)

### Help and Support

[How you can share your article](#) 

[Author rights information](#)

[A guide to publishing Open Access](#)



**L'Auteur Correspondant confirme et/ou sélectionne les détails de son affiliation.**

**L'affiliation est utilisée pour identifier les auteurs et à les correspondre à l'établissement membre de l'accord Couperin.**

**L'auteur ayant déjà fourni ces informations lors de la soumission ; elles sont pré-remplies.**

Corresponding author  
E-mail address  
Journal  
Article number  
Our reference  
PII  
DOI

### Corresponding Author's Organization ⓘ

Please enter the corresponding author's organization. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

**Hint:** start your search using your main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find your specific department, then selecting your main organization is sufficient. For more tips on searching for an organization please visit our [Support Center](#).

Organization name\*

- Nantes University
- Nantes University**  
Nantes, FR
- Nantes Universite  
Nantes, FR
- Nantes Université  
Nantes, FR
- University of Nantes  
Nantes, FR
- Centre Hospitalier Universitaire de Nantes  
Nantes, FR
- University Hospital Centre Nantes  
Nantes, FR
- Nantes University University Library

Save and Continue >

All content on t  
technologies.  
We use cookies

All rights are reserved, including those for text and data mining, AI training, and similar



**Ajout également les détails d'affiliation des co-auteurs**

Test article ▼

Were there any co-authors for this article?

Yes

No

### Add Co-author Details ?

Please provide details for all co-authors. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

**Hint:** start the organization search using the main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find the specific department, then selecting the main organization is sufficient. For more tips on searching for an organization please visit our [Support Center](#).

First name or initial*	Last name*	
<input type="text" value="John"/>	<input type="text" value="Head"/>	

Organization name\*

Or use recently selected organization

- Avignon Universite +
- KU Leuven +

[+ Add another co-author](#)

1

Corresponding  
Author

2

Co-Author

3

Research  
Funders

4

Publishing  
Options

5

Review Order


6

Confirmation

**Vous pouvez ajouter  
les détails du  
financier.**

**Ce dernier peut être  
l'institution affiliée  
ou non.**

**Dans ce cas, il s'agit  
de Milliman.**



Did the research in this article receive funding?

Yes

No

## Funder Details ⓘ

Determine the best publishing options for your article. Please include the details about any funding received outside of your primary affiliations. If providing details for two or more organizations, please list the organization(s) that provided the most funding first.

For tips on searching for an organization please visit our [Support Center](#)

Organization name\*

Milliman Inc



Grant/Contract numbers\*

GT123



+ Add grant/contract number

+ Add another organization

Previous

Save and Continue >

- Sur la base des détails de l'affiliation, s'affichent les options de publication. L'option Accès libre (Gold OA) est suivie de l'option « Subscription ». L'auteur est informé que l'accord couvre l'APC.
- Si le/la bibliothécaire/ administrateur de l'institution rejette la demande de l'auteur sur la plateforme, nous précisons également aux auteurs qu'ils recevront une facture sans réduction.
- Le parcours se suit quand l'auteur sélectionne OA Gold

## Gold Open Access

Publish as an Open Access article

Make my published article available to everyone.


As an author affiliated with the [Nantes University](#), upon validation, the [agreement between the French higher education and research institutions consortium \(Couperin\) and Elsevier](#) [↗](#) may cover the Article Publishing Charge.


Please check with your institution regarding the open access policy.

I and others can share and reuse my article in the ways described by the user license I select.

### Article Publishing Charge (APC)

Price  
EUR 3,120.00

 Institutional Agreement Discount  
- 3,120.00

 To pay (on validation)  
**0.00**

If your institution cannot confirm your affiliation, you will receive a full price invoice for EUR 3,120.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact [Researcher Support](#) to publish free of charge under the Subscription model.

[Couperin and Elsevier Agreement](#)

## Subscription

Publish as a subscription article

I will publish my article subscription, making my final published article immediately available to journal subscribers, and to other groups as part of [Elsevier's programs](#) [↗](#).

I understand I can immediately share my article within my institution and privately with collaborators, and share my accepted manuscript publicly in my institution's repository after 5 March 2025. I have additional article sharing rights outlined [here](#) [↗](#).

Previous

Save and Continue >



1

Corresponding Author

2

Co-Author

3

Research Funders

4

Publishing Options

5

Licenses

6

Rights

7

Publishing Agreement

8

Review Order


9

Confirmation



Publications sur Lancet ou Cell (remise APC)

- Indication à l'auteur qu'il devra fournir un bon de commande (en cours d'implémentation)



Based on information you have provided, your publishing option is shown below

## Gold Open Access

### Publish as an Open Access article

Make my published article available to everyone.

As an author affiliated with the **University of Lille**, upon validation, I will receive a 10% discount on the APC as part of the [agreement between the University of Lille and Elsevier](#).

I will need to enter the valid PO number in the PO number section below as it is mandatory. I can refer to this [link](#) to understand how I can receive a PO number for the institution. I will receive an invoice to pay the remainder of the APC from my institution.

I and others can share and reuse my article in the ways described by the user license I select.

Purchase order number \*

### Article Publishing Charge (APC)

Price  
EUR 4,880.00

Institutional Agreement Discount  
- 488.00



To pay (on validation)

(Excluding taxes)



EUR 4,392.00



If your institution cannot confirm your affiliation, you will receive a full price invoice for USD 5,460.00 (ex. VAT).

University of Lille and Elsevier Agreement

Add discount code >



### Select your user license


Please select your license. If you need to comply with a mandated license and the mandated license is not listed below, please visit our [Support Hub](#) for additional help.

- CC BY 4.0**  
[CC-BY license is the recommended choice]  
A license to permit readers to share and adapt your article for any purpose, even commercially.  
[Read more about CC BY 4.0](#) ▼
- CC BY-NC-ND 4.0**  
A license to permit readers to share all or part of your article in any medium or format for non-commercial purposes. Permission from Elsevier is required for the distribution of derivative versions of the article or for commercial use.  
[Read more about CC BY-NC-ND 4.0](#) ▼
- CC BY-NC 4.0**  
A license for readers to share and adapt your article for non-commercial purposes. Permission from Elsevier is required for commercial use of the article.  
[Read more about CC BY-NC 4.0](#) ▼

- **Le système présente différentes option de licence Creative Commons.**
- **CC BY 4.0 est pré-sélectionné.**

Previous

Save and Continue >



L'auteur informe son status pour signature de l'accord de publication

How best to disseminate your work: [View options](#)

Elsevier B.V.

### Select Your Status

- I am the sole author of the manuscript
  - I am one author signing on behalf of all co-authors of the manuscript
- Please indicate which of the below applies to you:
- We are all US Government employees and the Article is public domain and therefore the 'License of publishing rights' clause does not apply
  - I am a US Government employee but some of my co-authors are not
  - I am not a US Government employee but some of my co-authors are
  - The work was performed by contractors of the US Government under contract number:
  - All or some of the authors are UK, Canadian or Australian Government employees and Crown Copyright is asserted
  - Some of the authors are employees of the UK, Canadian or Australian Government but Crown Copyright is not asserted
  - None of the above
  - I am signing as an authorized representative and on behalf of my employer

### Signed on Behalf of Corresponding Author

Please complete this section if you are not the corresponding author as listed above. A copy of the agreement will be sent to you and the corresponding author.

I am signing on behalf of the corresponding author

Previous

Save and Continue >

1

Corresponding  
Author

2

Co-Author

3

Research  
Funders

4

Publishing  
Options

5

Licenses

6

Rights

7

Publishing  
Agreement

8

Payment  
Details

9

Review Order

10

Confirmation



Elsevier B.V.

### Your Status

- I am one author signing on behalf of all co-authors of the manuscript

**Le système présente  
l'accord de publication de la  
licence du journal.**

**L'accord de licence non  
exclusive pour la licence CC  
BY.**

### License of Publishing Rights

I hereby grant to Elsevier B.V. an irrevocable non-exclusive license to publish, distribute and otherwise use all or any part of the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in all forms and media (whether now known or later developed) in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication.

I acknowledge the importance of the integrity, authenticity and permanence of the scholarly record and agree that the version of the Article that appears or will appear in the journal and embodies all value-adding publisher activities (including peer review co-ordination, copy-editing, formatting, (if relevant) pagination, and online enrichment) shall be the definitive final record of published research ("the Published Journal Article").

I further acknowledge and agree that nothing in this Agreement shall be deemed to permit redundant/duplicate publication of the Article in violation of publishing ethics principles, as further described below.

### Supplemental Materials

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

## L'auteur indique l'acceptation des Termes et Conditions

### Author representations

- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses which conflict with the terms of this License Agreement.
- If I and/or any of my co-authors reside in Russia, Belarus, Iran, Cuba, or Syria, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See <https://www.elsevier.com/about/our-business/policies/patient-consent> ↗ for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.


### Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of Elsevier B.V. ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see <http://www.elsevier.com/copyright> ↗.

I have read and agree to the terms of the License Agreement.


## Rights and Access



## Une fois que l'auteur a cliqué sur

## Terminer :

- L'auteur correspondant et les coauteurs reçoivent une copie du résumé par e-mail
- L'article devient en libre accès sur ScienceDirect dans les 24 heures
- Le bibliothécaire/ administrateur de l'établissement recevra une notification de validation dans les 48 heures qui dispose ensuite de 3 semaines pour valider la demande
- Si le bibliothécaire/ administrateur approuve la demande, les coûts de l'APC seront couverts
- Si le bibliothécaire/ administrateur rejette la demande; L'auteur aura le choix de payer ou de publier en souscription gratuitement



## Review Order

Research Funders	Milliman Inc Grant numbers: GT123
Publishing Option	Gold Open Access
User License	CC BY 4.0
Publishing Agreement	<ul style="list-style-type: none"> <li>I am one author signing on behalf of all co-authors of the manuscript and I am duly authorized to do so by all co-authors of the manuscript</li> </ul> <p>I may share my final published article widely in accordance with the <a href="#">user License</a> that I have selected. Further details on <a href="#">Elsevier Sharing Policy here</a>.</p>

6 June 2024

Previous

## Total payment due

Price (excluding taxes)

EUR 3,120.00

Institutional Agreement Discount



- 3,120.00

To pay (on validation)



0.00

If your institution cannot confirm your affiliation, you will receive a full price invoice for EUR 3,120.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact [Researcher Support](#) to publish free of charge under the Subscription model.

[Couperin and Elsevier Agreement](#)

Finish &gt;

## Support aux auteurs et aux bibliothécaires/administrateurs

- Pour les auteurs – [oasupport@elsevier.com](mailto:oasupport@elsevier.com)
- Pour les bibliothécaires/Administrateurs, relatif à l'activation ou aux modifications d'EOAP– [agreementactivation@elsevier.com](mailto:agreementactivation@elsevier.com)
- Equipe APC Couperin: [apc@couperin.org](mailto:apc@couperin.org)

### Liens

[Hub client Couperin \(elsevier.com\)](#)

[Elsevier < Couperin](#)

[Find a journal | Journal Finder  
\(elsevier.com\)](#)